The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Substance Abuse and Mental Health Services Administration Friday awarded $450 million in grants, including $250 million in emergency COVID-19 funding, to…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Sens. Joe Manchin, D-W.Va., and Shelley Moore Capito, R-W.Va., this week reintroduced the Protecting Jessica Grubb’s Legacy Act (S. 3374), AHA-supported…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing titled “Combatting an Epidemic: Legislation to Help Patients with Substance Use…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…